ReviewAntibiotics (Basel, Switzerland)2020
Transitioning of
Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Empirical therapy versus tailored therapy for Helicobacter pylori infection? A systematic review.BMC infectious diseases · 2025Pooled it
- Randomized multicenter trial comparing minocycline and ornidazole with classical quadruple therapy in Helicobacter pylori treatment.Scientific reports · 2025Trial
- National and Regional US Antibiotic Resistance to Helicobacter pylori: Lessons From a Clinical Trial.Gastroenterology · 2021Trial
- Real-World Observational Clinical Study Assessing the Effectiveness and Safety of Vonoprazan-Based Dual Therapy Versus Proton Pump Inhibitor-Based Triple Therapy forGastroenterology research · 2026Article
- Economic Evaluation of Empirical and Tailored Helicobacter pylori Eradication Strategies Including Second-Line Therapy.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
- Controversies in management of Helicobacter pylori infection from a U.S. perspective: population screening and treatment.Minerva gastroenterology · 2025Review
- Review
- Review
- Overcoming the effects of increasing antimicrobial resistance onExpert review of gastroenterology & hepatology · 2024Review
- Predictors of Successful First-LineAntibiotics (Basel, Switzerland) · 2024Article
- Review
- Success of susceptibility-guided eradication ofWorld journal of gastroenterology · 2024Article
- Novel therapeutic regimens againstFrontiers in microbiology · 2024Review
- Subinhibitory concentrations of antibiotics affect development and parameters ofFrontiers in pharmacology · 2024Article
- The use of non-invasive stool tests for verification of Helicobacter pylori eradication and clarithromycin resistance.United European gastroenterology journal · 2023Article
- Antibiotic Resistance, Susceptibility Testing and Stewardship inInternational journal of molecular sciences · 2023Review
- From Antibiotic Resistance to Antibiotic Renaissance: A New Era in Helicobacter pylori Treatment.Cureus · 2023Review
- How widespread and convenientExpert review of gastroenterology & hepatology · 2023Review
- Implications of the paradigm shift in management ofTherapeutic advances in gastroenterology · 2023Review
- Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice.Life (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.